Prima BioMed Ltd. (NASDAQ:PBMD) has received a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.
Analysts have set a 1 year consensus price objective of $5.00 for the company, according to Zacks. Zacks has also given Prima BioMed an industry rank of 105 out of 265 based on the ratings given to related companies.
A number of equities analysts have weighed in on PBMD shares. Zacks Investment Research raised shares of Prima BioMed from a “sell” rating to a “hold” rating in a research report on Thursday, September 29th. FBR & Co reissued a “buy” rating on shares of Prima BioMed in a research report on Friday, August 26th. Roth Capital reissued a “buy” rating and issued a $6.00 price objective on shares of Prima BioMed in a research report on Friday, August 26th. Maxim Group reaffirmed a “buy” rating and set a $5.00 price target on shares of Prima BioMed in a research report on Tuesday, July 12th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Prima BioMed in a research report on Wednesday, June 22nd.
Prima BioMed (NASDAQ:PBMD) opened at 0.889 on Friday. The company has a 50-day moving average price of $0.89 and a 200 day moving average price of $0.95. Prima BioMed has a 12 month low of $0.72 and a 12 month high of $1.54. The firm’s market cap is $61.09 million.
Prima BioMed Company Profile
Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prima BioMed Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.